GlaxoSmithKline has acquired rights to several inhaled drug candidates manufactured using Liquidia Technologies’ PRINT (Particle Replication In Non-Wetting Templates) platform. The PRINT nanofabrication technology produces particles with narrow size distribution and any desired shape.
According to Liquidia, the total value of the deal, including an upfront payment, milestone payments, and royalties could be “several hundred million dollars.” Liquidia has retained the right to develop other respiratory therapies using the PRINT platform.
Liquidia CEO Neal Fowler commented, “We are very pleased to have the opportunity to work with GSK, a company known for its commitment to scientific excellence, medicinal chemistry expertise and expansive library of proprietary compounds that could potentially benefit from Liquidia’s PRINT technology. The strength of this collaboration is based on the strong and successful heritage of GSK’s vaccine and inhaled therapy franchises and the transformative particle engineering and manufacturing capabilities of Liquidia’s PRINT technology, which when combined, we believe will yield a next generation of life saving therapeutics.”
Read the Liquidia press release.
